Medical device company Colospan revealed on Tuesday the addition of Gregory D. Casciaro to its board of directors.

Casciaro will help lead the company forward to improve the lives of patients and positively impact healthcare economics with its novel solution that is designed to address the unmet needs of anastamotic leaks, diverting stoma and their related complications. The IDE approved, multi-centre randomized trial is enrolling rectal cancer patients in 13 participating hospitals across the US, Israel and Europe.

Most recently, Casciaro has served as the president and CEO of Cardiac Dimension.

Previously, Casciaro worked as the chief executive officer of of AccessClosure, XTENT, Orquest as well as General Surgical Innovations, respectively.